| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2014) |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| ATC: | C01CA27 |
| UNII: | J7A92W69L7 |
Structure
| InChI Key | QXWYKJLNLSIPIN-JGVFFNPUSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C9H11NO5 |
| Molecular Weight | 213.19 |
| AlogP | -0.46 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 5.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 124.01 |
| Molecular species | ZWITTERION |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 15.0 |
Pharmacology
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 1
Nuclear hormone receptor subfamily 1 group I
Nuclear hormone receptor subfamily 1 group I member 2
|
4-3200 | - | - | - | - |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Hypotension, Orthostatic | 4 | D007024 | ClinicalTrials |
| Multiple System Atrophy | 4 | D019578 | ClinicalTrials |
| Hypotension | 2 | D007022 | ClinicalTrials |
| Parkinson Disease | 2 | D010300 | ClinicalTrials |
| Attention Deficit Disorder with Hyperactivity | 2 | D001289 | ClinicalTrials |
| Fibromyalgia | 2 | D005356 | ClinicalTrials |
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 23651-95-8 |
| ChEBI | 31524 |
| ChEMBL | CHEMBL2103827 |
| DrugBank | DB06262 |
| DrugCentral | 971 |
| FDA SRS | J7A92W69L7 |
| Guide to Pharmacology | 7391 |
| PubChem | 92974 |
| SureChEMBL | SCHEMBL134299 |
| ZINC | ZINC000001482049 |
CONTENTS